Mesoblast Aktie
WKN DE: A2AA6U / ISIN: US5907171046
01.07.2025 18:13:50
|
Mesoblast Stock Gains 12% On FDA Alignment For Revascor BLA Submission
(RTTNews) - Mesoblast Limited (MESO) rose 12.40 percent to $12.24 on Tuesday after announcing it reached alignment with the FDA on requirements to file a Biologics License Application for Revascor, aimed at treating ischemic heart failure patients with reduced ejection fraction and inflammation.
Shares opened at $12.00, moved between $11.72 and $12.50 on the Nasdaq, and traded 254,644 shares, above the 206,195 averages, as investors welcomed the FDA progress.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Mesoblast Ltd. (spons. ADRs)mehr Nachrichten
Keine Nachrichten verfügbar. |